Novel Mps1 kinase inhibitors with potent antitumor activity

AM Wengner, G Siemeister, M Koppitz, V Schulze… - Molecular cancer …, 2016 - AACR
AM Wengner, G Siemeister, M Koppitz, V Schulze, D Kosemund, U Klar, D Stoeckigt…
Molecular cancer therapeutics, 2016AACR
Abstract Monopolar spindle 1 (Mps1) has been shown to function as the key kinase that
activates the spindle assembly checkpoint (SAC) to secure proper distribution of
chromosomes to daughter cells. Here, we report the structure and functional characterization
of two novel selective Mps1 inhibitors, BAY 1161909 and BAY 1217389, derived from
structurally distinct chemical classes. BAY 1161909 and BAY 1217389 inhibited Mps1
kinase activity with IC50 values below 10 nmol/L while showing an excellent selectivity …
Abstract
Monopolar spindle 1 (Mps1) has been shown to function as the key kinase that activates the spindle assembly checkpoint (SAC) to secure proper distribution of chromosomes to daughter cells. Here, we report the structure and functional characterization of two novel selective Mps1 inhibitors, BAY 1161909 and BAY 1217389, derived from structurally distinct chemical classes. BAY 1161909 and BAY 1217389 inhibited Mps1 kinase activity with IC50 values below 10 nmol/L while showing an excellent selectivity profile. In cellular mechanistic assays, both Mps1 inhibitors abrogated nocodazole-induced SAC activity and induced premature exit from mitosis (“mitotic breakthrough”), resulting in multinuclearity and tumor cell death. Both compounds efficiently inhibited tumor cell proliferation in vitro (IC50 nmol/L range). In vivo, BAY 1161909 and BAY 1217389 achieved moderate efficacy in monotherapy in tumor xenograft studies. However, in line with its unique mode of action, when combined with paclitaxel, low doses of Mps1 inhibitor reduced paclitaxel-induced mitotic arrest by the weakening of SAC activity. As a result, combination therapy strongly improved efficacy over paclitaxel or Mps1 inhibitor monotreatment at the respective MTDs in a broad range of xenograft models, including those showing acquired or intrinsic paclitaxel resistance. Both Mps1 inhibitors showed good tolerability without adding toxicity to paclitaxel monotherapy. These preclinical findings validate the innovative concept of SAC abrogation for cancer therapy and justify clinical proof-of-concept studies evaluating the Mps1 inhibitors BAY 1161909 and BAY 1217389 in combination with antimitotic cancer drugs to enhance their efficacy and potentially overcome resistance. Mol Cancer Ther; 15(4); 583–92. ©2016 AACR.
AACR